Vince & Associates Clinical Research plans a $5 million addition

05/01/2014 7:39 PM

05/01/2014 7:39 PM

An Overland Park clinical research firm serving the biopharmaceutical industry is planning a three-story addition to upgrade its services, including suites for volunteers in overnight studies.

The firm, Vince & Associates Clinical Research, is investing $5 million in the 15,000-square-foot addition, which also will connect the firm’s headquarters at 10103 Metcalf Ave. with its early-development unit. The total complex will be 40,000 square feet when completed.

The firm already has added 20 employees in anticipation of the addition and intends to hire an additional 20 workers when it’s completed, bringing its total workforce to 170 people, said Brad Vince, CEO and medical director of Vince & Associates.

“The construction of this new three-story building will allow us to keep pace with demand from the global biopharmaceutical industry as well as provide a clear, strategic advance for Vince & Associates in the conduct of complex clinical trials,” Vince said.

The addition will accommodate what is described as an advanced medical-surgical suite for specialized clinical trials and research suites for volunteers participating in overnight clinical trials. Work is expect to begin within two weeks and be completed early next year.

The project will include a pharmacy that will provide additional capabilities for drug preparations along with a certified clean room.

The architect is RSA Architecture of Overland Park.

Vince & Associates has been providing clinical research to companies for 15 years and operates a 90-bed clinical pharmacology unit.

Videos

Join the discussion

is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service